174 results about "Vaccine antigen" patented technology

The invention discloses a broad-spectrum monoclonal antibody for resisting porcine epidemic diarrhea virus S protein and application of the broad-spectrum monoclonal antibody. Specifically, firstly, two monoclonal antibodies GC33D8-1 and GC33A4-3 which have broad-spectrum binding characteristics with the porcine epidemic diarrhea virus S protein are obtained, the GC33D8-1 antibody has good universality and can have strong affinity with different strains, and the GC33A4-3 antibody can be bound for 3 times. Secondly, the two monoclonal antibodies are respectively used as a capture antibody and a detection antibody, a double-antibody sandwich ELISA method is established, and the double-antibody sandwich ELISA method is applied to PEDV vaccine S protein quantification, has better parallelism compared with other antibodies, and can be widely applied to detection of different strains. The method can be used for detecting semi-finished products and finished products, can be used for process establishment and optimization of porcine epidemic diarrhea virus vaccine antigens, vaccine quality evaluation and stability monitoring, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, and solves the problems that broad-spectrum detection cannot be carried out at present and an S protein ELISA method only can be used for qualitative judgment.

The invention provides a construction method and application of a high-efficiency expression system based on a Seali forest virus replicon. The method comprises the following steps: constructing a saRNA system for expressing a reporter gene; constructing to obtain replicase providing plasmids in the taRNA system; constructing to obtain an antigen providing plasmid in the taRNA system; the method comprises the following steps: respectively linearizing pSFV-CMV-T7-X, pSFV-CMV-T7-TR-X and pSFV-CMV-T7-replicase, and then carrying out in vitro transcription to prepare mRNA (Messenger Ribonucleic Acid); transfecting the prepared mRNA into a host eukaryotic cell for expression according to a certain proportion to obtain an antigen protein; and detecting the antigen protein to evaluate the expression efficiency of the saRNA and taRNA system based on the SFV replicon. According to the self-amplification DNA and RNA vaccine based on the virus replicon, the development period can be shortened, and the vaccine antigen can be expressed at a high level.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

The invention discloses a method for detecting the content of monosaccharide components in bacterial capsular polysaccharide or a conjugate thereof, and belongs to the field of biological product detection. Taking pneumococcus as an example, different hydrolysis methods are adopted for different serotypes of capsular polysaccharides, connected glucosidic bonds are broken through hydrolysis, released monosaccharide components and 1-phenyl-3-methyl-5-pyrazolone are subjected to derivatization under the alkaline condition to generate derivatives with ultraviolet absorption, and then the capsular polysaccharides with different serotypes are obtained. And then detecting the composition and the content of each monosaccharide generated by polysaccharide hydrolysis through liquid chromatography. According to the method, each monosaccharide component can be quickly and effectively hydrolyzed, meanwhile, various polysaccharides with different structural characteristics can be separated and detected by adopting a derivatization method, whether the monosaccharide composition of each serotype polysaccharide accords with a theoretical structure or not can be qualitatively analyzed, and the content of each monosaccharide component can be quantitatively determined to calculate the content of the polysaccharides; and a better technical support is provided for quality control of the antigen component capsular polysaccharide of the bacterial vaccine.

The invention relates to the technical field of animal vaccines, and discloses an animal recombinant castration vaccine and a preparation method and application thereof, the animal recombinant castration vaccine comprises an animal castration vaccine antigen and an adjuvant, and the content of the animal castration vaccine antigen in the vaccine is 0.5-1 mg / mL. A gel type vaccine is prepared by adopting an animal castration vaccine antigen with an amino acid sequence as shown in SEQ ID No.2-4, and testis growth and development of rats are obviously inhibited after the rats are immunized. The animal castration vaccine antigen is also used for preparing vaccines in three dosage forms, namely an emulsion type vaccine, an aluminum salt type vaccine and a gel type vaccine, after the three vaccines are used for immunizing rats, the anti-GnRH antibody titer in the rats is obviously increased, the testosterone concentration is reduced (Plt; 0.05), and the testis growth and development are inhibited. The three dosage forms of vaccines all have good immune castration effect, and can be applied to castration or estrus inhibition of pets and economic animals in the future.

The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.

The invention discloses a monoclonal antibody and application thereof in quantitative detection of porcine epidemic diarrhea virus, and belongs to the technical field of biological detection. The preparation method comprises the following steps: firstly, obtaining two monoclonal antibodies GC44F3-1 and GC32C11-5 which specifically react with S protein of the porcine epidemic diarrhea virus; secondly, establishing a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) method by taking the two monoclonal antibodies as a coating antibody and a detection antibody respectively, and applying the double-antibody sandwich ELISA method to PEDV (Porcine Epidemic Diarrhea Virus) vaccine S protein quantification; the method can be used for detecting semi-finished products and finished products, can be used for process establishment, optimization, vaccine quality evaluation and stability monitoring of porcine epidemic diarrhea virus vaccine antigens, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, is high in detection flux and high in speed, solves the problem that TCID50 cannot meet vaccine quality evaluation at present, and has a good application prospect. The defect that the existing S protein ELISA method can only be used for qualitative judgment is overcome. The monoclonal antibody can also be used for blocking ELISA, capturing ELISA, indirect ELISA, competitive ELISA and a reagent for detecting the porcine epidemic diarrhea virus through a colloidal gold test strip.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention relates to a novel rabies virus nucleocapsid nanostructure vaccine and a construction method thereof, and belongs to the field of biomedicine.The nanostructure vaccine is characterized in that mRNA capable of efficiently expressing rabies virus G protein and recombinant rabies virus N protein expressed by escherichia coli are combined to form an NLS structure serving as a vaccine antigen component; and then wrapping with a lipid component. The vaccine constructed by the invention can form G antigen and N antigen integrated immunogen signal stimulation, so that specific immunity can form an effective reaction in humoral immunity and cellular immunity. In a protective test of challenge, the vaccine can achieve a 100% protection effect on mice.

The present disclosure relates to field of lyophilized / freeze-dried viral vaccine composition and methods for manufacturing and obtaining the vaccine composition comprising live attenuated flavivirus as vaccine antigen selected from a group of yellow fever virus, dengue virus, Japanese encephalitis (JE) virus, Kunjin virus, West Nile (WN) virus, tick-borne encephalitis (TBE) virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, Zika virus vaccine antigen; and stabilizers comprising sugar or sugar alcohol; amino acids; lactalbumin hydrolysate and gelatin. Post reconstitution, the composition preserves the desired characteristics of the virus, including immunogenicity and stability. The composition of the present disclosure can be safely administered subcutaneously or intramuscularly such that the vaccine composition induces complete immune response to yellow fever virus infectious agent and meets the criterion for the seroprotection for the said immunogenic components comprising yellow fever virus.

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

The invention relates to the technical field of biological medicines, in particular to a tuberculosis vaccine antigen and a vaccine. In particular to application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, in the application, the sequence of the Rv1787 gene or an encoding product thereof is defined, and the Rv1787 gene and the encoding product thereof serve as antigens, have mycobacterium tuberculosis specificity, and can be used for preparing a vaccine for preventing and / or treating tuberculosis. According to the mycobacterium tuberculosis vaccine, identification and response of an organism immune system to mycobacterium tuberculosis can be accurately stimulated, non-specific immune response to other normal tissues is avoided, a brand new and specific molecular target spot is provided for preventing and treating tuberculosis, and the limitation that a traditional vaccine depends on a single antigen or an attenuated strain is broken through. A specific expression product of the gene can stimulate directional recognition and attack of an organism immune system on mycobacterium tuberculosis, the pertinence and effectiveness of vaccines are remarkably improved, and a new path is provided for solving the problem of tuberculosis prevention and treatment.

The present invention relates to the technical field of biomedicine technology and vaccines, and particularly relates to an aluminum nanocrystal delivery system with a surface covered with an Fc affinity protein and a preparation method for a self-assembled particle adjuvant vaccine. An aluminum nanocrystal is used as a carrier, the surface of the aluminum nanocrystal is covered with an Fc affinity protein molecular layer and an antigen molecule, and the antigen of a recombinant Fc Tag specifically binds to an Fc affinity protein, so that antigen self-assembly is realized, a virus-like particle vaccine is formed, and the antigen density is improved. The present vaccine can generate a high-titer specific antibody by inducing a body fluid and cell immunity.

The application discloses a vaccine and a preparation method thereof, and the preparation method comprises the following steps: mixing an acidic protein antigen solution containing a phosphate buffer solution with an aluminum adjuvant to make the molar ratio of phosphorus and aluminum below 0.9, so as to obtain an acidic protein vaccine; or mixing the aluminum adjuvant with a solution containing phosphate ions to make the molar ratio of phosphorus and aluminum above 0.2, and then mixing the aluminum adjuvant with an alkaline protein antigen solution containing a phosphate buffer solution, so as to obtain an alkaline protein vaccine; wherein the acidic protein antigen is any kind of protein antigen with a net negative charge; and the alkaline protein antigen is any kind of protein antigen with a net positive charge. According to the preparation method, the molar ratio of phosphorus and aluminum is adjusted to a specific range according to the net charge of the protein antigen, so that the isoelectric point of the aluminum adjuvant can be effectively changed, the charge carried by the aluminum adjuvant is opposite to the charge carried by the protein antigen, and then the aluminum adjuvant and the protein antigen are attracted to each other through electrostatic interaction. The vaccine antigen prepared by the method has high antigen adsorption rate and good stability, the preparation method is simple, and the method is suitable for industrial application.

The present invention provides a fusion protein KP-Ag1 used as a Klebsiella pneumoniae vaccine antigen, which is composed of KP6 protein, KP21 protein and KP24 protein connected by a flexible amino acid Linker; wherein, the amino acid sequence of the KP6 is SEQ ID NO:4, the amino acid sequence of the KP21 is SEQ ID NO:5, and the amino acid sequence of the KP24 is SEQ ID NO:6. The present invention also provides its expression vector and recombinant engineering diagram, as well as its application as a Klebsiella pneumoniae antigen. The antigen protein prepared by the method described in the present invention can effectively stimulate the body to produce a higher humoral immune response, and can provide obvious protection against lethal-dose Klebsiella pneumoniae infection, and can be used as a candidate antigen for Klebsiella pneumoniae vaccine.

The application relates to the field of rapid detection of new coronaviruses, in particular to a single-layer MoS2 phase sensor detection box for a new coronavirus vaccine antigen protein and a detection method thereof. The process that a MoS2 test sample is combined with a standard new coronavirus SARS-CoV-2 antibody is as follows: firstly, single-layer MoS2 is grown through a CVD method; further, ZnO is deposited on SiO2 / Si through atomic layer deposition (ALD); the single-layer MoS2 is transferred to a substrate through PMMA (polymethyl methacrylate) assisted wet transfer; the surface of the MoS2 is subjected to surface treatment; and the problem that current detection methods can only qualitatively detect whether there is a new coronavirus and cannot measure a specific concentration is solved. On the premise of ensuring high sensitivity, the actual concentration of a sample can be quantitatively measured. The pretreatment process of the sample is simple, the detection process is short in time consumption, the measurement result is intuitive and accurate, and the application has important significance for quantitative detection of the concentration of a new coronavirus for a large number of samples.

Disclosed is a vaccine adjuvant comprising at least one inverse microlatex comprising at least one oil, at least one surfactant, at least one polymer, such as, for example, a fully or partially neutralized polyacrylate in the form of an alkali metal salt or an ammonium salt, which can be completely sterilized by filtration or by heating in an autoclave and can be emulsified in one step with an aqueous phase comprising only the vaccine antigen.

The invention relates to the technical field of biological medicines, and particularly discloses a diluent for a porcine pseudorabies live vaccine. The diluent for the porcine pseudorabies live vaccine is prepared by stirring and dissolving sodium dihydrogen phosphate, dipotassium phosphate, calcium chloride, sodium chloride, a traditional Chinese medicine extract, a stabilizer and water, and performing high-pressure steam sterilization, the traditional Chinese medicine extract is prepared by taking poria cocos and honeysuckle as traditional Chinese medicine raw materials and further reacting with chitosan and tannic acid, and the stabilizer is prepared by mixing gelatin, cyclodextrin and bovine serum albumin according to a mass ratio. When the diluent prepared by the method is used for diluting the porcine pseudorabies live vaccine, the stability and the activity of vaccine antigens can be effectively improved, the activity and the function of immune cells are enhanced, so that the immune effect of the vaccine is enhanced, and the prepared diluent for the porcine pseudorabies live vaccine solves the problem that a traditional live vaccine diluent does not have an immune enhancement effect.

Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.

The invention relates to a GnRH-I-M1 recombinant protein. A vaccine prepared from the GnRH-I-M1 recombinant protein is high in antigen purity and good in safety, and has a good castration effect.

The application provides a buffer for improving the stability of foot-and-mouth disease vaccine antigen, which contains milk serum, sodium chloride, sorbitol, glycine, K2HPO4.3H2O and KH2PO4. The buffer has the effects of improving the thermal stability of 146S antigen and obviously inhibiting the degradation of 146S antigen under the conditions of 4 DEG C and 37 DEG C. The antigen resuspended by the buffer and the prepared vaccine can be stored for a long time under the condition of 4 DEG C. In addition, the buffer is easy to prepare and dissolve, can be used as a medium for resuspending FMD antigen, is a good thermal stability protective agent for FMD antigen and vaccine, can be used in large-scale production, has strong practicability, can obviously reduce the degradation rate of effective antigen in foot-and-mouth disease vaccine under storage conditions and extreme conditions, and obviously improves the product quality.

The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.

The present invention discloses a monoclonal antibody capable of recognizing a novel duck reovirus NDRVσC protein, a preparation method and an application thereof, wherein the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises a V sequence as shown in SEQ ID NOs: 3, 4, and 5. H CDR1, V H CDR2 and V H CDR3, the light chain variable region includes the amino acid sequences shown in SEQ ID NOs: 6, 7, and 8. L CDR1, V L CDR2 and V L CDR3. The present invention also discloses a method for preparing a monoclonal antibody and a double-antibody sandwich ELISA method based on the antibody and the σC rabbit polyclonal antibody. This method can be used to quantify NDRV subunit vaccine antigens and determine animal immunization doses. Compared with the methods reported in the literature, this ELISA method is simpler to operate and has great potential for practical application. The present invention provides a new method for evaluating NDRV immune efficacy and controlling vaccine quality, which can ensure the upgrading of NDRV vaccines.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.

The invention belongs to the technical field of biological medicines, and discloses an EBV (Epstein-Barr Virus) tumor vaccine and application thereof. The invention discloses a novel EBV vaccine antigen combination for the first time. The novel EBV vaccine antigen combination comprises BZLF1, EBNA1, EBNA3B and gHgL. The applicant carries out antigen modification on BZLF1, EBNA1 and EBNA3B, and safety modification is completed while antigen T cell epitopes are retained. A humanized mouse proves that the antigen combination has good safety, immunity and protection effects, and EBV infected cells can be killed by activating BZLF1, EBNA1 and EBNA3B antigen specific T cells, so that EBV tumors are effectively prevented. The vaccine of the antigen combination can be used for preventing EBV related tumors, such as lymphoma, lymphatic proliferative diseases after transplantation, nasopharynx cancer and gastric cancer.

This invention relates to a homogeneous photocatalytic chemiluminescence detection system for detecting HPV vaccine antigen content, its preparation method, and its application. The system utilizes self-made carboxyl-modified donor microspheres and receptor microspheres, coupled with HPV type-specific monoclonal antibodies via EDC / NHS activation, achieving one-step homogeneous detection. By optimizing the microsphere size, a 200 nm microsphere system was found to exhibit higher luminescence signal, a wider detection range, and better sensitivity when detecting HPV16 / 18 VLPs. This method is simple to operate, requires no plate washing, and possesses good specificity, accuracy, and precision. It is suitable for the in vitro relative potency and identification detection of bivalent HPV vaccines, and can replace traditional ELISA methods, reducing detection costs and safety risks. It is also suitable for large-scale applications in vaccine quality control.